![PSA test gets a better grade from USPSTF—it's a “C” Uncertainty lingers about high-risk groups](https://cdn.cancerletter.com/media/2018/05/prostate-exam-web.jpg)
![PSA test gets a better grade from USPSTF—it's a “C” Uncertainty lingers about high-risk groups](https://cdn.cancerletter.com/media/2018/05/prostate-exam-web.jpg)
Cover Story
Relying largely on maturing data from the European trials of screening for prostate cancer, the U.S. Preventive Services Task Force has given a better grade—a “C”—to screening for prostate cancer.
By Matthew Bin Han Ong
In Brief
Funding Opportunities
Clinical Roundup
Drugs & Targets
Trending Stories
- Federal judge blocks Trump administration’s move to limit indirect costs to 15% for NIH-funded institutions
The move could gut academic cancer research - FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers
- What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - “Page Not Found:” HHS agencies purge web pages that hint at DEI, health equity, and gender
Medical group sues over removing “information used every day by health professions” - Beyond the $500B Stargate Project: The frontier of AI in oncology beckons
- Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills